The company’s lead rare disease asset, Cortrophin Gel , grew from $198 million to $347 million in 2025, a year-over-year increase of 76%. ANI’s 2026 guidance calls for Cortrophin Gel sales of $540 million to $575 million, representing growth of 55% to 65%.ANI’s rare disease business generated $423 million of revenue in 2025, up 84% year-over-year, according to Lalwani. The company expects rare disease revenue to grow to $618 million to $658 million in 2026—an increase of 51%—which would make it about 60% of ...